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ABSTRACT
Objective: To assess at 24months corrected age (CA) the neurological, respiratory, and general
health status of children born prematurely from 27þ0 to 33þ6 weeks’ gestation who were
treated in a first-in-human study with a new fully synthetic surfactant (CHF5633) enriched with
SP-B and SP-C proteins.
Outcome measures: Children were assessed using Bayley Scales of Infant Development (BSID),
with a score below normal defined as BSID-II Mental Development Index score <70, or BSID-III
cognitive composite score <85. In addition, a health status questionnaire was used to check for
functional disability including respiratory problems and related treatments, sensory and neuro-
development assessments, communication skills as well as the number of hospitalizations.
Results: 35 of 39 survivors had a neurodevelopmental assessment, 24 infants being evaluated
by Bayley’s Scales and 11 by health status questionnaires only. 23 children had scores within
normal limits and one had BSID-III <85. The remaining 11 were judged clinically to have normal
development. Health status questionnaires detected only issues that would normally be
expected in preterm-born children.
Conclusions: This assessment offers reassurance that treatment with CHF5633 surfactant was
not associated with adverse neurodevelopmental, respiratory, or health outcomes by two years
corrected age.
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CHF5633 is a new intratracheally administered, fully
synthetic surfactant enriched with peptide analogs of
human SP-B and SP-C proteins which was tested in a
first-in-human study at two different doses (100 and
200mg/kg) in two cohorts of 20 preterm neonates
with respiratory distress syndrome (RDS). The main
phase of the study from birth until hospital discharge
demonstrated a good safety and tolerability profile of
both endotracheal doses without detectable systemic
absorption nor immunogenicity and with encouraging
efficacy results [1]. At 2 years of age, the neurological,
respiratory, and general health status of study patients
was evaluated in agreement with standard local prac-
tice at the participating centres.
Materials and methods
According to the initial study protocol and consent
form, investigators invited families of preterm infants
born between 27þ0 and 33þ6 weeks’ gestation with
RDS who participated in the main initial phase of the
CONTACT David G. Sweet david.sweet@belfasttrust.hscni.net Neonatal Unit, Royal Maternity Hospital, Grosvenor Road, Belfast BT12 6BB,
Northern Ireland
 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-
nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed,
or built upon in any way.
THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
https://doi.org/10.1080/14767058.2020.1863363
study to attend a clinical visit at the recruiting site at
24months (±3months) corrected age (CA). The aim
was where possible to perform a neurological clinical
assessment based on the Bayley Scales of Infant
Development (BSID) as well as a respiratory and gen-
eral health status evaluation by questionnaire. Preterm
infants who were included in the first-in-human study
had to have clinical and radiological findings of mild
to moderate RDS, needing a fraction of inspired oxy-
gen concentration (FiO2) 0.35 on continuous positive
airways pressure (CPAP) to maintain pre-ductal pulse
oximeter oxygen saturation (SpO2) in the range
90–95%, and they were treated with endotracheal
CHF5633 at a dose of either 100 or 200mg/kg [1].
BSID scores are a series of measurements to assess the
motor, language, and cognitive development of
infants and toddlers. According to the standard of
practice and the Bayley scale version in use at each
participating site, we used either the Mental
Developmental Index (MDI) from Bayley Scale of Infant
and Toddler Development - Second edition (BSID-II) or
the Cognitive score from Bayley Scale of Infant and
Toddler Development - Third edition (BSID-III).
In addition, a health status questionnaire was used
to assess health and to check for functional disability,
including diagnosis of cerebral palsy, need for ven-
tricular shunting, presence of seizures or other neuro-
logical problems, visual, hearing, speech or language
problems, need for home oxygen, pulmonary prob-
lems and related medications as well as re-hospitaliza-
tions during the first two years of life. When a formal
neurodevelopmental assessment could not be con-
ducted at the recruiting sites, the visit was replaced
by a contact/phone call with the parents/carers or
family pediatricians to collect as much information as
possible based on the health status questionnaire.
Statistical analysis
This was a stand-alone assessment at 2 years of age of
ex-premature infants who participated in a first-in-
human trial mainly aimed at evaluating the safety of
two CHF5633 surfactant doses. Because of the nature of
Phase-I clinical trials, there were no controls. All clinical
data were summarized by descriptive statistics by the
dose administered to each treatment group. Continuous
variables were summarized using the n, mean, standard
deviation (SD), 95% confidence interval (CI), median,
minimum, and maximum value. Categorical variables
were summarized using frequency distributions. BSID
scores below the normal range were defined as BSID-II
MDI score <70 or BSID-III cognitive composite score
<85 [2].
Results
Overall, 35 of 39 surviving children were assessed (17/
20 from the 100mg/kg and 18/19 from the 200mg/kg
cohort) (Figure 1). Most were Caucasian (94%) with a
mean (SD) corrected age at the time of assessment of
25 (2.03) months. 51% were male. Four children from
the original cohort of 39 survivors were not able to be
assessed, for one child the parents refused consent
and three other families had moved address and could
not be contacted.
With regards to Bayley assessments, a total of 18/
35 children were assessed with BSID-III and 6/35 with
version II. Bayley’s scores were not available for 11/35
children. For three of them, Bayley’s assessment was
not available at their site at all, and for the remaining
8, it was not their site’s standard of care if the infant
had an apparently normal development. In these
cases, parent interviews and clinical assessment were
used for a global qualitative assessment of the child’s
development. Overall the mean (SD) BSID-II MDI score
was 105 (16) and the BSID-III cognitive composite
score was 95 (12). Only one child was below the nor-
mal range in the 100mg/kg group with a BSID-III cog-
nitive composite score of 70. Another child (200mg/kg
group) was diagnosed with spastic bilateral cerebral
palsy caused by cystic periventricular leukomalacia,
one child (100mg/kg group) had permanent hearing
impairment, well managed using hearing aids. A total
of 3/17 children (18%) in the 100mg/kg group and 4/
18 children (22%) children in the 200mg/kg group
had some difficulties with speech or language devel-
opment (Table 1).
None of the children in either dosing cohort ever
needed home oxygen. A total of 6/17 children (35%)
Neonates Treated  
04=N
100 mg/kg CHF5633  200 mg/kg CHF5633 
02=N02=N
Neonates Discontinued (Deaths)  Neonates Discontinued (Deaths) 
1=N0=N
Neonates Completed  Neonates Completed 
91=N02=N
Children evaluated at 24 months  Children evaluated at 24 months 
81=N71=N
Figure 1. Patients’ disposition.
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in the 100mg/kg group and 9/18 children (50%) in
the 200mg/kg group required at least one re-hospital-
ization after discharge for a mean (SD) of 5.3 (4.4)
nights and 6.9 (7.3) nights respectively. The mean (SD)
number of hospitalizations per patient was similar
between the treatment groups: 1.5 (0.55) for the
100mg/kg and 1.6 (0.88) for the 200mg/kg cohort. 1/
17 children (5.9%) in the 100mg/kg cohort required
mechanical ventilation and 3/18 children (16.7%) in
the 200mg/kg cohort received intensive care during
re-hospitalization. One child in the 100mg/kg cohort
and two in the 200mg/kg cohort were on regular
medications for wheezing. No other abnormalities
sometimes found in premature-born children were
detected (ventricular shunt, motor impairment, nystag-
mus, strabismus) at the 24-month follow up.
Discussion
This is a descriptive analysis of the results of a stand-
alone clinical assessment at approximately 24months
CA on the developmental and the general health sta-
tus of children who had participated as preterm neo-
nates with RDS in the first-in-human, two dosing
cohort (100 and 200mg/kg) clinical trial of a new syn-
thetic surfactant CHF5633 administered within 48 h of
life [1]. Follow-up studies conducted in similar late
preterm neonates treated with commercially available
surfactants have not to date identified any increases
in major neurodevelopmental or pulmonary sequelae
in surviving children [3, 4]. However considering that
this was a first-in-human study, we deemed it appro-
priate to conduct a 24-month stand-alone clinical
assessment in accordance with the standard practice
at each participating site to evaluate the long-term
outcomes in this mild to moderate RDS population to
confirm no evidence of harm.
As this was a first-in-human trial, there was no con-
trol arm with whom this cohort could be compared. It
must be borne in mind that the original study group
was preterm infants born between 27þ0 and 33þ6
weeks’ gestation who had been treated for RDS. The
risk of cerebral palsy increases with decreasing gesta-
tion, the prevalence being about 6% in babies born
between 28 and 31 weeks’ gestation, therefore it is not
surprising that one of the CHF5633 dosing cohorts,
went on to develop spastic diplegia, and unlikely that
this was causally related to the drug [5]. Likewise, there
is also a well-known association between prematurity
and expressive and receptive language delay [6].
Overall, one child from the 100mg/kg group, who
had a good short-term response to CHF5633, was
below the normal range on the BSID-III assessment,
however, without any other major abnormalities nor
re-hospitalizations in the first 24months of life.
The average MDI (BSID-II) score was 105 and the
average Cognitive composite score (Bayley-III) was 95
in this population. Bayley-III scores usually up to 7
points higher than MDI scores [7]. There were appar-
ently no big differences in clinical characteristics and
disease severity between the two groups at birth.
Considering the low number of children evaluated
with the BSID-II compared to BSID-III (6 vs. 18, respect-
ively) in different sites, the explanation of this differ-
ence is not clear and is likely to have occurred by
chance. Re-hospitalizations during this period were
Table 1. Outcomes of Cognitive Development Assessment and Health Status Questionnaire.
100mg/kg cohort, n¼ 17 200mg/kg cohort, n¼ 18
Cognitive Development Assessment
BSID-II normal, n (%) 5 (29) 1 (6)
BSID-III normal, n (%) 9 (53) 8 (44)
BSID-III below normal range, n (%) 1 (6) 0 (0)
Clinician’s judgment of normal development, n (%) 2 (12) 9 (50)
Health Status Questionnaire
Neurological problems
Cerebral palsy, n (%) 0 (0) 1 (6)
V-P shunt, n (%) 0 (0) 0 (0)
Seizures, n (%) 0 (0) 0 (0)
Visual impairment, n (%) 0 (0) 0 (0)
Hearing impairment, n (%) 1 (6) 0 (0)
Delayed language development, n (%) 3 (18) 4 (22)
Respiratory problems
Home oxygen, n (%) 0 (0) 0 (0)
Re-hospitalisationa, n (%) 6 (35) 9 (50)
Wheezing in the last year, n (%) 1 (6) 2 (11)
Regular medications for chest problems, n (%) 1 (6) 1 (6)
Relievers (e.g. short acting b2 agonists), n (%) 1 (6) 1 (6)
Preventers (e.g. inhaled corticosteroids), n (%) 1 (6) 0 (0)
BSID: Bayley Scales of Infant Development.
aBetween discharge and date of assessment.
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also checked. No relevant associated neurological or
developmental issues were observed in the two treat-
ment groups.
The number and type of health problems reported
by parents were the sorts of issues that would normally
be expected in the enrolled study population of preterm
born children. Re-hospitalisation within the early years of
life is a well-recognized complication of prematurity. In a
cohort of survivors born at less than 32weeks in
Australia, around two-thirds required readmission, mostly
for respiratory morbidity [8]. The CHF5633 cohort’s
readmission rates were less than this, presumably on the
basis that only relatively well preterm neonates were
selected for inclusion in the initial first-in-human trial
phase, however, it is reassuring that the children were
no more likely to need hospital care over the first 2 years
than expected. The absence of an excess of children
with wheeze requiring treatment was also reassuring.
In conclusion, clinical outcomes observed at two
years corrected age indicate that the administration of
CHF5633 at doses of 100 and 200mg/kg of birth weight
was not associated with impaired neurodevelopmental,
respiratory, or health consequences, taking into account
the level of prematurity of the babies recruited in the
initial phase of this first-in-human study. These data will
hopefully be confirmed in the on-going 24-month
assessment of the children evaluated in the phase II trial
comparing the effectiveness and safety of CHF5633 with
a natural surfactant in an even more preterm popula-
tion of neonates with higher RDS severity.
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